Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer

Author(s): Mahruba Sultana Niloy, Md. Salman Shakil, Md. Meharab Hassan Alif and Rhonda J. Rosengren*

Volume 28, Issue 39, 2021

Published on: 28 February, 2021

Page: [8098 - 8115] Pages: 18

DOI: 10.2174/0929867328666210301105856

Price: $65

Abstract

Approximately 85% of all lungs cancer cases are classified as non-small cell lung cancer (NSCLC). Kirsten rat sarcoma (KRAS) viral oncogene homolog mutations frequently occur in NSCLC patients resulting in a decreased overall survival. Additionally, currently used chemotherapeutic drugs lack selectivity,and patients experience side effects. Therefore, potent therapeutic agents are urgently needed for these patients. Plant- based compounds could be a potential option to treat KRAS-mutated NSCLC. These compounds are reported to be effective against the KRAS-linked up-stream and downstream signaling pathways that are directly or indirectly linked with cell proliferation, division, and apoptosis. Additionally, plant phytochemicals also suppressed different cell cycle phases of KRAS-mutant NSCLC cells. Furthermore, phytochemicals have a wider therapeutic index compared to chemotherapeutic drugs. Therefore, phytochemicals could benefit NSCLC patients as sole agents or as a combination therapy with approved chemotherapies. The current review aims to summarize the potential benefit of natural compounds in KRAS-mutant NSCLC.

Keywords: KRAS, NSCLC, phytochemicals, cell signaling, cell cycle, and apoptosis.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy